U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

Contributed by: Business Wire

Logo

Tags

Oncology

FDA

Health

Clinical Trials

Pharmaceutical

Biotechnology

BRUKINSA, FDA, lymphocytic leukemia

More Like This

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024